Cetrorelix Acetate (145672-81-7)

  • For any enquiries about this API or any of Tofigh Daru’s other products, please contact:
  • Contact Us >>

Product Detail


Cetrorelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion. It competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. The suppression of LH, which is more pronounced than FSH, is maintained by continuous treatment. An initial release of endogenous gonadotropins has not been detected with Cetrorelix, which is consistent with an antagonist effect.
Some studies suggest that LHRH antagonists, such as cetrorelix, inhibit the gene expression of pituitary LHRH receptor indirectly by counteracting the stimulatory effect of LHRH.

Packaging: glass vial

Storage conditions: Store between 2- 8°C , protected from light

CAS Number:  145672-81-7

Formula:  C70H92ClN17O14.xC2H4O2

Molecular Weight:1431.04 (free base basis)

Method of Analysis:  In house monograph


Cetrorelix is a synthetic decapeptide and an injectable gonadotropin-releasing hormone (GnRH) antagonist. It is used in assisted reproduction to inhibit premature luteinizing hormone (LH) surges. This is because GnRH controls LH, which is the hormone that starts ovulation during the menstrual cycle. When undergoing hormone treatment sometimes premature ovulation can occur, leading to eggs that are not ready for fertilization to be released. Cetrorelix does not allow the premature release of these eggs to occur.
In addition, cetrorelix can be used to treat hormone-sensitive cancers of the prostate and breast (in pre-/perimenopausal women) and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning).